vs
Side-by-side financial comparison of Alliance Laundry Holdings Inc. (ALH) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Alliance Laundry Holdings Inc. is the larger business by last-quarter revenue ($437.6M vs $281.3M, roughly 1.6× Guardant Health, Inc.). Alliance Laundry Holdings Inc. runs the higher net margin — 7.5% vs -45.7%, a 53.2% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 13.9%). Alliance Laundry Holdings Inc. produced more free cash flow last quarter ($87.0M vs $-54.2M).
Alliance Laundry Systems LLC is an American provider of commercial laundry systems. The company designs, manufactures, and markets a line of commercial and industrial laundry equipment under various brands in over 100 countries. Among the company's products are washers, drying tumblers and ironers for the coin laundry, multi-housing laundries, institutional laundries and laundries for consumer residences. Alliance Laundry Systems manufactures products under the brands Speed Queen, Primus, Hue...
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
ALH vs GH — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $437.6M | $281.3M |
| Net Profit | $32.9M | $-128.5M |
| Gross Margin | 37.0% | 64.6% |
| Operating Margin | 19.5% | -43.0% |
| Net Margin | 7.5% | -45.7% |
| Revenue YoY | 13.9% | 39.4% |
| Net Profit YoY | 620.3% | -15.8% |
| EPS (diluted) | $0.19 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $281.3M | ||
| Q3 25 | $437.6M | $265.2M | ||
| Q2 25 | — | $232.1M | ||
| Q1 25 | — | $203.5M | ||
| Q4 24 | — | $201.8M | ||
| Q3 24 | $384.3M | $191.5M | ||
| Q2 24 | — | $177.2M | ||
| Q1 24 | — | $168.5M |
| Q4 25 | — | $-128.5M | ||
| Q3 25 | $32.9M | $-92.7M | ||
| Q2 25 | — | $-99.9M | ||
| Q1 25 | — | $-95.2M | ||
| Q4 24 | — | $-111.0M | ||
| Q3 24 | $-6.3M | $-107.8M | ||
| Q2 24 | — | $-102.6M | ||
| Q1 24 | — | $-115.0M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | 37.0% | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | 37.2% | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
| Q4 25 | — | -43.0% | ||
| Q3 25 | 19.5% | -37.3% | ||
| Q2 25 | — | -45.9% | ||
| Q1 25 | — | -54.6% | ||
| Q4 24 | — | -62.4% | ||
| Q3 24 | 18.7% | -61.3% | ||
| Q2 24 | — | -56.8% | ||
| Q1 24 | — | -59.2% |
| Q4 25 | — | -45.7% | ||
| Q3 25 | 7.5% | -35.0% | ||
| Q2 25 | — | -43.0% | ||
| Q1 25 | — | -46.8% | ||
| Q4 24 | — | -55.0% | ||
| Q3 24 | -1.6% | -56.3% | ||
| Q2 24 | — | -57.9% | ||
| Q1 24 | — | -68.2% |
| Q4 25 | — | $-1.01 | ||
| Q3 25 | $0.19 | $-0.74 | ||
| Q2 25 | — | $-0.80 | ||
| Q1 25 | — | $-0.77 | ||
| Q4 24 | — | $-0.90 | ||
| Q3 24 | $-0.04 | $-0.88 | ||
| Q2 24 | — | $-0.84 | ||
| Q1 24 | — | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.2M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $-136.4M | $-99.3M |
| Total Assets | $2.9B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $378.2M | ||
| Q3 25 | $136.2M | $580.0M | ||
| Q2 25 | — | $629.1M | ||
| Q1 25 | — | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | $128.4M | $585.0M | ||
| Q2 24 | — | $933.7M | ||
| Q1 24 | — | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-99.3M | ||
| Q3 25 | $-136.4M | $-354.5M | ||
| Q2 25 | — | $-305.5M | ||
| Q1 25 | — | $-250.8M | ||
| Q4 24 | — | $-139.6M | ||
| Q3 24 | $-284.6M | $-60.1M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | — | $68.3M |
| Q4 25 | — | $2.0B | ||
| Q3 25 | $2.9B | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $116.8M | $-26.4M |
| Free Cash FlowOCF − Capex | $87.0M | $-54.2M |
| FCF MarginFCF / Revenue | 19.9% | -19.3% |
| Capex IntensityCapex / Revenue | 6.8% | 9.9% |
| Cash ConversionOCF / Net Profit | 3.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-26.4M | ||
| Q3 25 | $116.8M | $-35.4M | ||
| Q2 25 | — | $-60.3M | ||
| Q1 25 | — | $-62.7M | ||
| Q4 24 | — | $-64.5M | ||
| Q3 24 | — | $-51.1M | ||
| Q2 24 | — | $-94.0M | ||
| Q1 24 | — | $-30.3M |
| Q4 25 | — | $-54.2M | ||
| Q3 25 | $87.0M | $-45.8M | ||
| Q2 25 | — | $-65.9M | ||
| Q1 25 | — | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | — | $-55.3M | ||
| Q2 24 | — | $-99.1M | ||
| Q1 24 | — | $-37.2M |
| Q4 25 | — | -19.3% | ||
| Q3 25 | 19.9% | -17.3% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | — | -28.9% | ||
| Q2 24 | — | -55.9% | ||
| Q1 24 | — | -22.1% |
| Q4 25 | — | 9.9% | ||
| Q3 25 | 6.8% | 3.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 4.1% |
| Q4 25 | — | — | ||
| Q3 25 | 3.55× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALH
| Equipment Product Or Service | $275.7M | 63% |
| Other | $106.8M | 24% |
| Service Parts | $33.1M | 8% |
| Equipment Financing | $12.6M | 3% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
